Tarsus Pharmaceuticals, INC

Tarsus Pharmaceuticals announced robust second quarter 2026 financial results, with XDEMVY net sales surging 69% year-over-year, leading to an increased full-year sales forecast and strategic pipeline expansion.

Tarsus Pharmaceuticals announced a $125 million private placement equity financing, including common stock and pre-funded warrants, to fund clinical development and commercial activities.

Tarsus Pharmaceuticals announced a definitive agreement to acquire Alkeus Pharmaceuticals for approximately $450 million, bolstering its eye care pipeline with gildeuretinol for Stargardt disease.

Tarsus Pharmaceuticals announced the departure of its Chief Commercial Officer, Aziz Mottiwala, who is leaving to become CEO of a public medical device company.

Tarsus Pharmaceuticals has acquired iRenix Medical, gaining late-stage asset IRX-101 for $75 million to enhance its eye care portfolio.

Tarsus Pharmaceuticals, Inc. announced the results of its Annual Meeting of Stockholders held on June 25, 2026, including the election of directors and ratification of its independent auditor.

Tarsus Pharmaceuticals announced significant year-over-year revenue growth in Q2 2026, driven by XDEMVY sales, and provided updates on its promising pipeline candidates.

Tarsus Pharmaceuticals reported a significant increase in product sales for Q1 2026, driven by XDEMVY, while narrowing its net loss compared to the prior year.

Tarsus Pharmaceuticals announced significant revenue growth for its lead product XDEMVY in Q3 2025, alongside continued operating losses and strategic pipeline advancements.

Tarsus Pharmaceuticals announced a significant increase in product sales for XDEMVY, reducing net losses while advancing its pipeline candidates.

Tarsus Pharmaceuticals' Q1 2025 revenue surged, fueled by a significant increase in XDEMVY sales, alongside strategic financial moves to bolster its market position.

Tarsus Pharmaceuticals reports a significant increase in product sales for Q3 2024, primarily driven by the commercialization of XDEMVY.

Tarsus Pharmaceuticals, Inc. reports significant revenue growth from its flagship product XDEMVY, while continuing to advance its pipeline for ocular rosacea and Lyme disease prophylaxis.

Tarsus Pharmaceuticals' 10-K filing highlights successful XDEMVY launch with $180.1 million in sales, expansion plans in Europe and Japan, and a potential partnership for its Lyme disease program.

Tarsus Pharmaceuticals' 2023 annual report highlights the successful launch of XDEMVY for Demodex blepharitis and advancements in its pipeline, including positive clinical trial results for MGD, rosacea, and Lyme disease.

Katherine Goodrich, a Director at Tarsus Pharmaceuticals, Inc., received a stock option grant and Restricted Stock Units (RSUs) on June 25, 2026.

Andrew D. Goldberg, a Director at Tarsus Pharmaceuticals, Inc., received stock options and restricted stock units on June 25, 2026.

Tarsus Pharmaceuticals, Inc. reports that Director Scott W. Morrison was granted stock options and restricted stock units on June 25, 2026.

Director Wendy L. Yarno of Tarsus Pharmaceuticals, Inc. reported the acquisition of stock options and restricted stock units on June 25, 2026.

David E. Pyott, a Director at Tarsus Pharmaceuticals, received stock options and restricted stock units on June 25, 2026.

William J. Link, Ph.D., a director at Tarsus Pharmaceuticals, received stock options and restricted stock units as compensation for his services.

Tarsus Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 25, 2026, with key proposals including director elections and executive compensation.

Tarsus Pharmaceuticals will hold its annual stockholders meeting on June 12, 2025, to elect directors, vote on executive compensation, and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Tarsus Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 12, 2025, to vote on director elections, executive compensation, and auditor ratification.

Tarsus Pharmaceuticals will hold its annual stockholders meeting on June 13, 2024, to vote on director re-elections and the ratification of its accounting firm.

Tarsus Pharmaceuticals will hold its annual stockholders meeting virtually on June 13, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Janus Henderson Group Ltd. has amended its Schedule 13G filing, reporting a decrease in its beneficial ownership of Tarsus Pharmaceuticals, Inc. common stock to 6.5%.

Janus Henderson Group plc has reported a beneficial ownership of 5.3% in Tarsus Pharmaceuticals, Inc., holding 2,240,963 shares as of March 31, 2026.

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 3,600,000 shares, representing 8.46% of the outstanding common stock of Tarsus Pharmaceuticals, Inc. as of March 31, 2026.

Prudential Financial, Inc. disclosed a reduction in its beneficial ownership of Tarsus Pharmaceuticals, Inc. common stock to 4.3%.

Jennison Associates LLC has reported a 4.0% beneficial ownership of Tarsus Pharmaceuticals Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Tarsus Pharmaceuticals Inc. following an internal realignment.